Quantitative electroencephalography as a potential neurophysiological diagnostic biomarker of schizophrenia and first-episode psychosis: a systematic review of clinical implications - Report - MDSpire
Advertisement
Quantitative electroencephalography as a potential neurophysiological diagnostic biomarker of schizophrenia and first-episode psychosis: a systematic review of clinical implications
Clinical Report: Evaluating Quantitative Electroencephalography as a Biomarker
Overview
This systematic review evaluates the clinical significance of resting-state quantitative electroencephalography (qEEG) as a biomarker for schizophrenia and first-episode psychosis. Findings indicate characteristic qEEG alterations in chronic schizophrenia, while early psychosis shows inconsistent results, highlighting the need for standardized protocols.
Background
Schizophrenia is a prevalent psychiatric disorder affecting approximately 1% of the global population, with early diagnosis crucial for effective treatment. Traditional diagnostic methods rely heavily on subjective clinical assessments, which can delay appropriate care. The exploration of qEEG as a non-invasive biomarker offers potential for improved diagnostic accuracy and early intervention.
Data Highlights
Study Type
Patient Cohorts
Key Findings
Systematic Review
1242 patients (981 SCZ, 261 FEP) vs. 1211 controls
Increased delta and theta activity in chronic SCZ; decreased alpha peak frequency
Key Findings
Chronic schizophrenia patients show increased delta and theta wave activity in anterior regions.
Decreased alpha peak frequency is observed in posterior areas of chronic schizophrenia patients.
First-episode psychosis patients exhibit less pronounced qEEG alterations compared to chronic cases.
The novel theta/alpha component (6–9 Hz) may provide mechanistic insights into alpha slowing.
Significant methodological heterogeneity among studies limits the ability to perform meta-analysis.
Clinical Implications
The findings suggest that qEEG may serve as a valuable tool for distinguishing chronic schizophrenia from healthy controls, but its application in early psychosis remains uncertain. Clinicians should be aware of the methodological limitations and the need for standardized protocols before integrating qEEG into routine diagnostic practices.
Conclusion
While qEEG shows promise as a neurophysiological biomarker for schizophrenia, further research and standardization are essential to enhance its clinical utility and reliability.
